News Headlines Article

New target: UCSF researchers eye common cold drug to beat back multiple sclerosis
San Francisco Business Times

A common cold treatment and seven other drugs already approved for other conditions could help restore a protective coating eroded around neurons in multiple sclerosis patients, according to researchers led by a team at the University of California, San Francisco. UCSF is spearheading a 50-patient clinical trial of the most promising drug — an over-the-counter antihistamine branded by Novartis as Tavist — that is expected to be completed by the end of the year. Patients still can enroll in the trial.

Commands